Free Trial

NewAmsterdam Pharma (NAMS) Short Interest Ratio & Short Volume

NewAmsterdam Pharma logo
$18.51 -0.84 (-4.34%)
Closing price 05/21/2025 04:00 PM Eastern
Extended Trading
$18.50 -0.01 (-0.03%)
As of 05/21/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NewAmsterdam Pharma Short Interest Data

NewAmsterdam Pharma (NAMS) has a short interest of 5.42 million shares, representing 8.68% of the float (the number of shares available for trading by the public). This marks a 6.90% increase in short interest from the previous month. The short interest ratio (days to cover) is 5.5, indicating that it would take 5.5 days of the average trading volume of 635,325 shares to cover all short positions.

Current Short Interest
5,420,000 shares
Previous Short Interest
5,070,000 shares
Change Vs. Previous Month
+6.90%
Dollar Volume Sold Short
$103.68 million
Short Interest Ratio
5.5 Days to Cover
Last Record Date
April 30, 2025
Outstanding Shares
109,818,000 shares
Float Size
62,410,000 shares
Short Percent of Float
8.68%
Today's Trading Volume
468,343 shares
Average Trading Volume
635,325 shares
Today's Volume Vs. Average
74%
Short Selling NewAmsterdam Pharma?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for NewAmsterdam Pharma and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

NAMS Short Interest Over Time

NAMS Days to Cover Over Time

NAMS Percentage of Float Shorted Over Time

NewAmsterdam Pharma Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
4/30/20255,420,000 shares $103.68 million +6.9%8.7%5.5 $19.13
4/15/20255,070,000 shares $81.42 million -5.1%8.3%5.2 $16.06
3/31/20255,340,000 shares $109.31 million +23.0%9.4%5.4 $20.47
3/15/20254,340,000 shares $101.43 million +42.8%7.5%5.1 $23.37
2/28/20253,040,000 shares $63.84 million +4.5%5.4%3.1 $21.00
2/15/20252,910,000 shares $57.94 million +3.9%5.3%3.3 $19.91
1/31/20252,800,000 shares $62.41 million -6.4%4.6%3.1 $22.29
1/15/20252,990,000 shares $71.76 million +0.7%4.9%3.6 $24.00
12/31/20242,970,000 shares $76.33 million +15.1%5.5%3.9 $25.70
12/15/20242,580,000 shares $63.70 million -0.4%5.1%3.6 $24.69
11/30/20242,590,000 shares $51.41 million +156.4%6.0%4.6 $19.85
11/15/20241,010,000 shares $25.15 million +40.7%2.4%2.5 $24.90
10/31/2024718,000 shares $12.22 million +30.9%1.6%2.2 $17.02
10/15/2024548,700 shares $10.43 million +23.9%1.3%1.6 $19.00
9/30/2024443,000 shares $7.35 million +4.9%1.0%1.2 $16.60
9/15/2024422,500 shares $6.74 million -77.4%1.0%1.2 $15.96
8/31/20241,870,000 shares $30.71 million +10.7%4.3%5.5 $16.42
8/15/20241,690,000 shares $27.70 million +20.7%4.3%5.3 $16.39
7/31/20241,400,000 shares $23.97 million +716.8%3.5%5.8 $17.12
7/15/2024171,400 shares $3.36 million -22.4%0.4%1 $19.59
6/30/2024220,800 shares $4.24 million -15.0%0.6%1.2 $19.21
6/15/2024259,600 shares $4.98 million +5.4%0.7%1.5 $19.19
5/31/2024246,200 shares $4.62 million -10.3%0.6%1.4 $18.75
5/15/2024274,600 shares $5.44 million -26.8%0.4%1.5 $19.81
4/30/2024375,000 shares $8.18 million +11.9%1.0%1.7 $21.81
4/15/2024335,200 shares $6.62 million -0.8%0.9%1.4 $19.74
3/31/2024337,900 shares $7.99 million -1.9%0.9%1.4 $23.65
3/15/2024344,600 shares $7.59 million -6.0%1.0%1.5 $22.03
2/29/2024366,700 shares $8.38 million +38.3%1.1%1.7 $22.84
2/15/2024265,200 shares $5.22 million -2.7%0.8%1.3 $19.67
1/31/2024272,500 shares $5.58 million -44.0%0.8%1.8 $20.47
1/15/2024486,200 shares $8.52 million +16.0%1.5%3.1 $17.53
12/31/2023419,300 shares $4.68 million -1.9%1.3%3.8 $11.17
12/15/2023427,500 shares $4.59 million +114.7%1.2%3.9 $10.74
11/30/2023199,100 shares $1.94 million -3.8%0.6%1.7 $9.76
11/15/2023206,900 shares $2.06 million -43.8%0.6%2.1 $9.95
10/31/2023367,800 shares $3.31 million +267.8%1.1%2.6 $9.00
10/15/2023100,000 shares $725,000.00 -72.7%0.3%0.9 $7.25
9/30/2023366,200 shares $3.39 million +12.1%1.1%3.5 $9.25
9/15/2023326,700 shares $3.27 million +1.0%1.0%3.2 $10.00
A grave, grave error. (Ad)

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

8/31/2023323,600 shares $3.34 million -0.5%0.9%3.2 $10.31
8/15/2023325,100 shares $3.58 million +29.7%0.9%3 $11.00
7/31/2023250,700 shares $2.89 million -0.4%0.7%3.7 $11.52
7/15/2023251,700 shares $3.01 million -12.7%0.7%3.6 $11.96
6/30/2023288,400 shares $3.43 million +53.3%0.8%4.2 $11.89
6/15/2023188,100 shares $2.29 million +3.2%0.5%3.1 $12.17
5/31/2023182,200 shares $2.53 million -47.5%0.6%3.9 $13.86
5/15/2023347,300 shares $4.29 million No Change1.1%10.2 $12.34

NAMS Short Interest - Frequently Asked Questions

What is NewAmsterdam Pharma's current short interest?

Short interest is the volume of NewAmsterdam Pharma shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 5,420,000 shares of NAMS short. 8.68% of NewAmsterdam Pharma's shares are currently sold short. Learn More on NewAmsterdam Pharma's current short interest.

What is a good short interest ratio for NewAmsterdam Pharma?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NAMS shares currently have a short interest ratio of 6.0. Learn More on NewAmsterdam Pharma's short interest ratio.

Which institutional investors are shorting NewAmsterdam Pharma?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of NewAmsterdam Pharma: Jane Street Group LLC, Affinity Asset Advisors LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for NewAmsterdam Pharma?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 8.68% of NewAmsterdam Pharma's floating shares are currently sold short.

Is NewAmsterdam Pharma's short interest increasing or decreasing?

NewAmsterdam Pharma saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 5,420,000 shares, an increase of 6.9% from the previous total of 5,070,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is NewAmsterdam Pharma's float size?

NewAmsterdam Pharma currently has issued a total of 109,818,000 shares. Some of NewAmsterdam Pharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. NewAmsterdam Pharma currently has a public float of 62,410,000 shares.

How does NewAmsterdam Pharma's short interest compare to its competitors?

8.68% of NewAmsterdam Pharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to NewAmsterdam Pharma: Roivant Sciences Ltd. (12.03%), Revolution Medicines, Inc. (8.89%), Elanco Animal Health Incorporated (5.00%), Blueprint Medicines Co. (8.76%), BridgeBio Pharma, Inc. (11.68%), Verona Pharma plc (9.87%), TG Therapeutics, Inc. (14.56%), Grifols, S.A. (1.26%), Lantheus Holdings, Inc. (10.28%), Axsome Therapeutics, Inc. (8.53%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Spotify Technology S.A. ($4.67 billion), Charter Communications, Inc. ($4.58 billion), Capital One Financial Co. ($4.47 billion), The Kroger Co. ($2.56 billion), Reddit, Inc. ($2.23 billion), Rivian Automotive, Inc. ($2.16 billion), Live Nation Entertainment, Inc. ($1.90 billion), SoFi Technologies, Inc. ($1.85 billion), Zscaler, Inc. ($1.75 billion), and Omnicom Group Inc. ($1.75 billion). View all of the most shorted stocks.

What does it mean to sell short NewAmsterdam Pharma stock?

Short selling NAMS is an investing strategy that aims to generate trading profit from NewAmsterdam Pharma as its price is falling. NAMS shares are trading down $0.84 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against NewAmsterdam Pharma?

A short squeeze for NewAmsterdam Pharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of NAMS, which in turn drives the price of the stock up even further.

How often is NewAmsterdam Pharma's short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NAMS, twice per month. The most recent reporting period available is April, 30 2025.




This page (NASDAQ:NAMS) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners